CeleCor Announces Publication of Positive Clinical Results of RUC-4, a Novel Second Generation Platelet GPIIb/IIIa Inhibitor Designed for Subcutaneous Point-of-Care STEMI Therapy

SAN DIEGO–(BUSINESS WIRE)–CeleCor Therapeutics, Inc. announced positive clinical results of RUC-4 which was published in the Journal of the American Heart Association.